Cts Corp (CTS) · Oct 27, 2026 · Earnings
Beat — Adjusted EPS $0.77 vs ~$0.66 consensus; revenue $149.6M vs ~$146M
CTS earnings beat on revenue, adjusted EPS and margins, while the company raised 2026 guidance for a second time.
CTS is in the middle of a deliberate shift away from transportation dependence, using sensing, motion and connectivity products to build faster-growing medical, industrial, and aerospace-and-defense exposure. The Millar acquisition, completed shortly before this filing, adds medical pressure-sensing technology and is intended to deepen that diversification.
The quarter cleared expectations on both major measures. Adjusted diluted EPS was $0.77 versus roughly $0.66–$0.67 expected, while revenue was $149.6 million versus approximately $146 million consensus. That is a genuine earnings beat, not merely a margin-led result: revenue rose 5% year over year, adjusted gross margin reached 42.2% from 38.9%, and adjusted EBITDA margin increased to 24.7% from 23.8% (Adjusted Net Earnings and Adjusted Diluted EPS; Adjusted Gross Margin; Adjusted EBITDA Margin). External estimates also confirm the revenue and adjusted-EPS beat.
| Metric | Q3 2026 | Q3 2025 | Market expectation / change |
|---|---|---|---|
| Revenue | $149.6M | $143.0M | ~$146M consensus |
| GAAP EPS | $0.61 | $0.46 | — |
| Adjusted diluted EPS | $0.77 | $0.60 | ~$0.66–$0.67 consensus |
| Adjusted gross margin | 42.2% | 38.9% | +330 bps |
| Adjusted EBITDA margin | 24.7% | 23.8% | +90 bps |
| Operating cash flow | $43.5M | $29.0M | +$14.5M |
The underlying operating trend is better than the headline revenue growth suggests. Industrial revenue grew 13% year over year and medical revenue surged 33%, while transportation was flat; aerospace and defense declined 7% (Industrial; Medical; Aerospace & Defense; Transportation). That mix supports CTS’s diversification thesis, with the important caveat that defense weakness remains a drag. The adjusted EPS bridge also contains a $0.44-per-share discrete tax adjustment, but that was largely offset by removing a $0.43-per-share insurance recovery, making the quarter’s adjusted earnings signal cleaner than the raw reconciliation first appears (Adjusted Net Earnings and Adjusted Diluted EPS).
Management raised the full-year outlook again, making this more than a routine beat. FY 2026 revenue guidance is now $580–$590 million and adjusted EPS is $2.78–$2.88, versus the prior ranges of $565–$585 million and $2.55–$2.70. Those new ranges sit above published full-year expectations of roughly $573.5 million revenue and $2.65 EPS, so the filing increases the earnings trajectory rather than simply validating it.
Cash generation gives the upgrade credibility. Nine-month operating cash flow was $94.3 million and free cash flow was $82.3 million, compared with $72.9 million and $60.4 million respectively a year earlier (Free Cash Flow). That supports CTS’s stated ability to fund organic investment, acquisitions and shareholder returns, although the guidance still assumes stable market conditions and continued execution through tariff, geopolitical and vehicle-production uncertainty.
Bottom line: This filing advances CTS’s story on two fronts: the current business is outperforming expectations, and management is raising the bar again. The most meaningful improvement is the continued mix shift toward medical and industrial markets, though aerospace-and-defense weakness keeps the diversification transition uneven rather than complete.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!